Safety and efficacy of semorinemab in prodromal-to-mild Alzheimer’s disease: Preliminary analyses of the Phase 2 Tauriel study
This presentation will provide preliminary data from the Phase II Tauriel study. Tauriel enrolled participants aged 50-80 years with prodromal or mild Alzheimer's disease (AD), with evidence of cerebral amyloid pathology (amyloid PET or Elecsys® β-Amyloid(1–42) cerebrospinal fluid immunoassay). Participants were randomized to receive semorinemab at 1500, 4500, or 8100 mg IV or placebo IV every 2 weeks for doses 1–3 and every 4 weeks thereafter for 72 weeks. Primary analyses were conducted at Week 73. The primary endpoint was change in CDR-SB from baseline.
{{assetTitle}}
{{assetDescription}}
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.